Follow the people · Insider
Jean Francois Formela
Jean Francois Formela files insider transactions with the SEC as a director of Korro Bio (KRRO). We hold 9 disclosed purchases and sales filed since 3 February 2006, 8 of them in the last 90 days.
- Files forKRRO
- Disclosed buys and sells9 in all, 8 in the last 90 days
- Last disclosure28 August 2026
Positions held
11 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 3 November 2023 — 26 August 2026Director · Korro Bio (KRRO)27 Form 4 lines · source: SEC Form 4
- Filed 21 December 2020 — 7 June 2024Director · Ikena Oncology (IKNA)16 Form 4 lines · source: SEC Form 4
- Filed 5 May 2016 — 14 June 2022Director · Intellia Therapeutics (NTLA)63 Form 4 lines · source: SEC Form 4
- Filed 2 July 2018 — 14 September 2021Director · Translate Bio (TBIO)18 Form 4 lines · source: SEC Form 4
- Filed 6 November 2017 — 17 August 2021Director · Spero Therapeutics (SPRO)16 Form 4 lines · source: SEC Form 4
- Filed 11 February 2014 — 11 February 2014Director and 10% owner · Egalet (EGLT)11 Form 4 lines · source: SEC Form 4
- Filed 27 February 2009 — 22 October 2012Director and 10% owner · ARCA biopharma (ABIO)7 Form 4 lines · source: SEC Form 4
- Filed 2 August 2011 — 2 March 2012Director and 10% owner · Horizon Pharma (HZNP)15 Form 4 lines · source: SEC Form 4
- Filed 31 October 2006 — 14 December 2007Director and 10% owner · Achillion Pharmaceuticals (ACHN)5 Form 4 lines · source: SEC Form 4
- Filed 1 February 2006 — 17 May 2007Director and 10% owner · Sgx Pharmaceuticals (SGXP)7 Form 4 lines · source: SEC Form 4
- Filed 26 May 2006 — 26 May 2006Director and 10% owner · NxStage Medical (NXTM)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 249 shares of Korro BioSEC Form 428 August 2026Common Stock · traded 26 August 2026 · filed 28 August 2026
- ▼ sold on the open market 51 shares of Korro BioSEC Form 428 August 2026Common Stock · traded 26 August 2026 · filed 28 August 2026
- ▼ sold on the open market 23,584 shares of Korro BioSEC Form 421 August 2026Common Stock · traded 19 August 2026 · filed 21 August 2026
- ▼ sold on the open market 4,884 shares of Korro BioSEC Form 421 August 2026Common Stock · traded 19 August 2026 · filed 21 August 2026
- ▼ sold on the open market 1,775 shares of Korro BioSEC Form 413 August 2026Common Stock · traded 11 August 2026 · filed 13 August 2026
- ▼ sold on the open market 368 shares of Korro BioSEC Form 413 August 2026Common Stock · traded 11 August 2026 · filed 13 August 2026
- ▼ sold on the open market 85,955 shares of Korro BioSEC Form 47 July 2026Common Stock · traded 2 July 2026 · filed 7 July 2026
- ▼ sold on the open market 14,745 shares of Korro BioSEC Form 47 July 2026Common Stock · traded 2 July 2026 · filed 7 July 2026
- ▼ sold on the open market 817 shares of Korro BioSEC Form 47 July 2026Common Stock · traded 6 July 2026 · filed 7 July 2026
- ▼ sold on the open market 8,506 shares of Korro BioSEC Form 47 July 2026Common Stock · traded 6 July 2026 · filed 7 July 2026
- ▼ sold on the open market 3,382 shares of Korro BioSEC Form 424 June 2026Common Stock · traded 22 June 2026 · filed 24 June 2026
- ▼ sold on the open market 580 shares of Korro BioSEC Form 424 June 2026Common Stock · traded 22 June 2026 · filed 24 June 2026
- ▼ sold on the open market 101,579 shares of Korro BioSEC Form 424 June 2026Common Stock · traded 23 June 2026 · filed 24 June 2026
- ▼ sold on the open market 17,426 shares of Korro BioSEC Form 424 June 2026Common Stock · traded 23 June 2026 · filed 24 June 2026
- ▼ sold on the open market 40,679 shares of Korro BioSEC Form 424 June 2026Common Stock · traded 24 June 2026 · filed 24 June 2026
- ▼ sold on the open market 666 shares of Korro BioSEC Form 424 June 2026Common Stock · traded 24 June 2026 · filed 24 June 2026
- ▼ sold on the open market 6,979 shares of Korro BioSEC Form 424 June 2026Common Stock · traded 24 June 2026 · filed 24 June 2026
- ▼ sold on the open market 114 shares of Korro BioSEC Form 424 June 2026Common Stock · traded 24 June 2026 · filed 24 June 2026
- was granted 14,677 shares of Korro Bio (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 10 June 2026 · filed 11 June 2026
- ▼ sold on the open market 2,441 shares of Korro BioSEC Form 41 June 2026Common Stock · traded 28 May 2026 · filed 1 June 2026
- ▼ sold on the open market 419 shares of Korro BioSEC Form 41 June 2026Common Stock · traded 28 May 2026 · filed 1 June 2026
- was granted 6,010 shares of Korro Bio (a derivative holding)SEC Form 412 June 2025Stock Option (Right to Buy) · traded 11 June 2025 · filed 12 June 2025
- was granted 5,190 shares of Korro Bio (a derivative holding)SEC Form 412 June 2024Stock Option (Right to Buy) · traded 11 June 2024 · filed 12 June 2024
- was granted 17,520 shares of Ikena Oncology (a derivative holding)SEC Form 410 June 2024Stock Option (Right to Buy) · traded 7 June 2024 · filed 10 June 2024
- was granted 17,857 shares of Korro BioSEC Form 423 April 2024Common Stock · traded 22 April 2024 · filed 23 April 2024
- was granted 16,000 shares of Korro Bio (a derivative holding)SEC Form 47 November 2023Stock Option (Right to Buy) · traded 3 November 2023 · filed 7 November 2023
- was granted 942,075 shares of Korro BioSEC Form 47 November 2023Common Stock · traded 3 November 2023 · filed 7 November 2023
- was granted 177,217 shares of Korro BioSEC Form 47 November 2023Common Stock · traded 3 November 2023 · filed 7 November 2023
- was granted 17,520 shares of Ikena Oncology (a derivative holding)SEC Form 413 June 2023Stock Option (Right to Buy) · traded 9 June 2023 · filed 13 June 2023
- was granted 7,688 shares of Intellia Therapeutics (a derivative holding)SEC Form 416 June 2022Stock Option (right to buy) · traded 14 June 2022 · filed 16 June 2022
- was granted 5,197 shares of Intellia TherapeuticsSEC Form 416 June 2022Common Stock · traded 14 June 2022 · filed 16 June 2022
- was granted 13,419 shares of Ikena Oncology (a derivative holding)SEC Form 413 June 2022Stock Option (Right to Buy) · traded 9 June 2022 · filed 13 June 2022
- was granted 13,419 shares of Ikena Oncology (a derivative holding)SEC Form 423 December 2021Stock Option (Right to Buy) · traded 21 December 2021 · filed 23 December 2021
- ▲ bought on the open market 125,000 shares of Ikena OncologySEC Form 414 December 2021Common Stock · traded 30 March 2021 · filed 14 December 2021
- ▼ sold on the open market 11,989 shares of Ikena OncologySEC Form 414 December 2021Common Stock · traded 10 December 2021 · filed 14 December 2021
- ▼ sold on the open market 8,330 shares of Ikena OncologySEC Form 414 December 2021Common Stock · traded 13 December 2021 · filed 14 December 2021
- ▼ sold on the open market 5,959 shares of Ikena OncologySEC Form 414 December 2021Common Stock · traded 14 December 2021 · filed 14 December 2021
- ▼ sold on the open market 18,900 shares of Translate Bio (a derivative holding)SEC Form 414 September 2021Stock Option (right to buy) · traded 14 September 2021 · filed 14 September 2021
- ▼ sold on the open market 18,900 shares of Translate Bio (a derivative holding)SEC Form 414 September 2021Stock Option (right to buy) · traded 14 September 2021 · filed 14 September 2021
- ▼ sold on the open market 20,000 shares of Translate Bio (a derivative holding)SEC Form 414 September 2021Stock Option (right to buy) · traded 14 September 2021 · filed 14 September 2021
- ▼ sold on the open market 37,800 shares of Translate Bio (a derivative holding)SEC Form 414 September 2021Stock Option (right to buy) · traded 14 September 2021 · filed 14 September 2021
- ▼ sold on the open market 2,055,063 shares of Translate BioSEC Form 414 September 2021Common Stock · traded 14 September 2021 · filed 14 September 2021
- was granted 7,500 shares of Spero Therapeutics (a derivative holding)SEC Form 418 August 2021Stock Option (right to buy) · traded 17 August 2021 · filed 18 August 2021
- ▼ sold on the open market 26,019 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 55,525 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 56,280 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 48,724 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 66,468 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 53,823 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 56,188 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 36,519 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 30,831 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 21,893 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 3,033 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 5,400 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 4,201 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 52,320 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 8,027 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 8,420 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 13,556 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- ▼ sold on the open market 6,149 shares of Intellia TherapeuticsSEC Form 429 June 2021Common Stock · traded 28 June 2021 · filed 29 June 2021
- was granted 3,382 shares of Intellia Therapeutics (a derivative holding)SEC Form 425 June 2021Stock Option (right to buy) · traded 23 June 2021 · filed 25 June 2021
- was granted 2,094 shares of Intellia TherapeuticsSEC Form 425 June 2021Common Stock · traded 23 June 2021 · filed 25 June 2021
- was granted 20,000 shares of Translate Bio (a derivative holding)SEC Form 417 June 2021Common Stock (right to buy) · traded 16 June 2021 · filed 17 June 2021
- ▼ sold on the open market 29,071 shares of Intellia TherapeuticsSEC Form 415 June 2021Common Stock · traded 11 June 2021 · filed 15 June 2021
- ▼ sold on the open market 1,875 shares of Intellia TherapeuticsSEC Form 415 June 2021Common Stock · traded 11 June 2021 · filed 15 June 2021
- ▼ sold on the open market 16,293 shares of Intellia TherapeuticsSEC Form 415 June 2021Common Stock · traded 14 June 2021 · filed 15 June 2021
- ▼ sold on the open market 47,422 shares of Intellia TherapeuticsSEC Form 415 June 2021Common Stock · traded 14 June 2021 · filed 15 June 2021
- ▼ sold on the open market 93,102 shares of Intellia TherapeuticsSEC Form 415 June 2021Common Stock · traded 14 June 2021 · filed 15 June 2021
- ▼ sold on the open market 13,309 shares of Intellia TherapeuticsSEC Form 415 June 2021Common Stock · traded 14 June 2021 · filed 15 June 2021
- ▼ sold on the open market 653 shares of Intellia TherapeuticsSEC Form 415 June 2021Common Stock · traded 14 June 2021 · filed 15 June 2021
- ▼ sold on the open market 4,513 shares of Intellia TherapeuticsSEC Form 430 April 2021Common Stock · traded 29 April 2021 · filed 30 April 2021
- ▼ sold on the open market 806 shares of Intellia TherapeuticsSEC Form 428 April 2021Common Stock · traded 26 April 2021 · filed 28 April 2021
- ▼ sold on the open market 79,714 shares of Intellia TherapeuticsSEC Form 428 April 2021Common Stock · traded 27 April 2021 · filed 28 April 2021
- ▼ sold on the open market 68,836 shares of Intellia TherapeuticsSEC Form 428 April 2021Common Stock · traded 27 April 2021 · filed 28 April 2021
- ▼ sold on the open market 61,680 shares of Intellia TherapeuticsSEC Form 428 April 2021Common Stock · traded 27 April 2021 · filed 28 April 2021
- ▼ sold on the open market 102,186 shares of Intellia TherapeuticsSEC Form 428 April 2021Common Stock · traded 28 April 2021 · filed 28 April 2021
- ▼ sold on the open market 29,740 shares of Intellia TherapeuticsSEC Form 428 April 2021Common Stock · traded 28 April 2021 · filed 28 April 2021
- ▼ sold on the open market 800 shares of Intellia TherapeuticsSEC Form 47 April 2021Common Stock · traded 5 April 2021 · filed 7 April 2021
- was granted 5,362,888 shares of Ikena Oncology (a derivative holding)SEC Form 41 April 2021Series B Preferred Stock · traded 21 December 2020 · filed 1 April 2021
- converted 9,499,999 shares of Ikena Oncology (a derivative holding)SEC Form 41 April 2021Series A Preferred Stock · traded 30 March 2021 · filed 1 April 2021
- converted 11,258,117 shares of Ikena Oncology (a derivative holding)SEC Form 41 April 2021Series A-1 Preferred Stock · traded 30 March 2021 · filed 1 April 2021
- converted 7,863,094 shares of Ikena Oncology (a derivative holding)SEC Form 41 April 2021Series A-2 Preferred Stock · traded 30 March 2021 · filed 1 April 2021
- converted 5,362,888 shares of Ikena Oncology (a derivative holding)SEC Form 41 April 2021Series B Preferred Stock · traded 30 March 2021 · filed 1 April 2021
- converted 2,901,609 shares of Ikena OncologySEC Form 41 April 2021Common Stock · traded 30 March 2021 · filed 1 April 2021
- converted 1,099,118 shares of Ikena OncologySEC Form 41 April 2021Common Stock · traded 30 March 2021 · filed 1 April 2021
- converted 749,634 shares of Ikena OncologySEC Form 41 April 2021Common Stock · traded 30 March 2021 · filed 1 April 2021
- ▼ sold on the open market 501,945 shares of Intellia TherapeuticsSEC Form 41 March 2021Common Stock · traded 26 February 2021 · filed 1 March 2021
- ▼ sold on the open market 56,536 shares of Translate BioSEC Form 423 December 2020Common Stock · traded 21 December 2020 · filed 23 December 2020
- ▼ sold on the open market 79,865 shares of Translate BioSEC Form 423 December 2020Common Stock · traded 22 December 2020 · filed 23 December 2020
- ▼ sold on the open market 2,700 shares of Translate BioSEC Form 423 December 2020Common Stock · traded 22 December 2020 · filed 23 December 2020
- was granted 7,500 shares of Spero Therapeutics (a derivative holding)SEC Form 427 October 2020Stock Option (right to buy) · traded 27 October 2020 · filed 27 October 2020
- ▼ sold on the open market 34,410 shares of Translate BioSEC Form 427 August 2020Common Stock · traded 25 August 2020 · filed 27 August 2020
- ▼ sold on the open market 44,381 shares of Translate BioSEC Form 427 August 2020Common Stock · traded 26 August 2020 · filed 27 August 2020
- ▼ sold on the open market 10,097 shares of Translate BioSEC Form 427 August 2020Common Stock · traded 27 August 2020 · filed 27 August 2020
- was granted 19,000 shares of Intellia Therapeutics (a derivative holding)SEC Form 419 June 2020Stock Option (right to buy) · traded 18 June 2020 · filed 19 June 2020
- was granted 18,900 shares of Translate Bio (a derivative holding)SEC Form 417 June 2020Stock Option (right to buy) · traded 16 June 2020 · filed 17 June 2020
- was granted 5,408 shares of Spero Therapeutics (a derivative holding)SEC Form 46 January 2020Stock Option (right to buy) · traded 2 January 2020 · filed 6 January 2020
- was granted 18,900 shares of Translate Bio (a derivative holding)SEC Form 419 June 2019Stock Option (right to buy) · traded 18 June 2019 · filed 19 June 2019
- was granted 6,073 shares of Spero Therapeutics (a derivative holding)SEC Form 45 June 2019Stock Option (right to buy) · traded 5 June 2019 · filed 5 June 2019
- was granted 19,000 shares of Intellia Therapeutics (a derivative holding)SEC Form 422 May 2019Stock Option (right to buy) · traded 21 May 2019 · filed 22 May 2019
- ▼ sold on the open market 5,284 shares of Intellia TherapeuticsSEC Form 418 July 2018Common Stock · traded 16 July 2018 · filed 18 July 2018
- ▼ sold on the open market 1,402 shares of Intellia TherapeuticsSEC Form 418 July 2018Common Stock · traded 16 July 2018 · filed 18 July 2018
- converted 3,832,010 shares of Translate BioSEC Form 43 July 2018Common Stock · traded 2 July 2018 · filed 3 July 2018
- converted 12,925,244 shares of Translate Bio (a derivative holding)SEC Form 43 July 2018Series A Preferred Stock · traded 2 July 2018 · filed 3 July 2018
- converted 5,838,230 shares of Translate Bio (a derivative holding)SEC Form 43 July 2018Series B Preferred Stock · traded 2 July 2018 · filed 3 July 2018
- converted 2,525,253 shares of Translate Bio (a derivative holding)SEC Form 43 July 2018Series C Preferred Stock · traded 2 July 2018 · filed 3 July 2018
- ▼ sold on the open market 5,286 shares of Intellia TherapeuticsSEC Form 420 June 2018Common Stock · traded 19 June 2018 · filed 20 June 2018
- ▼ sold on the open market 1,400 shares of Intellia TherapeuticsSEC Form 420 June 2018Common Stock · traded 19 June 2018 · filed 20 June 2018
- was granted 6,073 shares of Spero Therapeutics (a derivative holding)SEC Form 46 June 2018Stock Option (right to buy) · traded 5 June 2018 · filed 6 June 2018
- was granted 19,000 shares of Intellia Therapeutics (a derivative holding)SEC Form 421 May 2018Stock Option (right to buy) · traded 17 May 2018 · filed 21 May 2018
- ▼ sold on the open market 6,686 shares of Intellia TherapeuticsSEC Form 417 May 2018Common Stock · traded 16 May 2018 · filed 17 May 2018
- ▼ sold on the open market 2,617 shares of Intellia TherapeuticsSEC Form 422 March 2018Common Stock · traded 20 March 2018 · filed 22 March 2018
- ▼ sold on the open market 36,628 shares of Intellia TherapeuticsSEC Form 422 March 2018Common Stock · traded 20 March 2018 · filed 22 March 2018
- converted 245,605 shares of Spero TherapeuticsSEC Form 47 November 2017Common Stock · traded 6 November 2017 · filed 7 November 2017
- converted 246,272 shares of Spero TherapeuticsSEC Form 47 November 2017Common Stock · traded 6 November 2017 · filed 7 November 2017
- converted 328,992 shares of Spero TherapeuticsSEC Form 47 November 2017Common Stock · traded 6 November 2017 · filed 7 November 2017
- converted 513,318 shares of Spero TherapeuticsSEC Form 47 November 2017Common Stock · traded 6 November 2017 · filed 7 November 2017
- converted 602,589 shares of Spero TherapeuticsSEC Form 47 November 2017Common Stock · traded 6 November 2017 · filed 7 November 2017
- ▲ bought on the open market 428,571 shares of Spero TherapeuticsSEC Form 47 November 2017Common Stock · traded 6 November 2017 · filed 7 November 2017
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.